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Abstract
 
Human immunodeficiency virus (HIV) 1 major histocompatibility complex (MHC) I–restricted
epitopes are widely believed to be derived from viral proteins encoded by primary open reading
frames. However, the HIV-1 genome contains alternative reading frames (ARFs) potentially
encoding small polypeptides. We have identified a panel of epitopes encoded by ARFs within
the 
 
gag
 
, 
 
pol
 
, and 
 
env
 
 genes. The corresponding epitopic peptides were immunogenic in mice
humanized for MHC-I molecules. In addition, cytotoxic T lymphocytes recognizing these
epitopes were found in HIV-infected patients. These results reveal the existence of atypical
mechanisms of HIV-1 epitope generation. They indicate that the repertoire of epitopes recog-
nized by the cellular anti–HIV-1 immune response is broader than initially thought. This should
be taken into account when designing vaccine strategies aimed at activating these responses.
Key words: HLA-B7 • CTL • transgenic mice • KO mice
 
Introduction
 
Cellular immunity plays an important role in the pathogenesis
of HIV-1 infection. HIV-1–specific CD8
 
 
 
 CTLs are involved
both in the initial decrease of viremia during acute infection
and in limiting viral replication in chronic stages of the disease
(1–5). In vitro studies have demonstrated inhibition of
HIV-1 replication by CTLs, by both lytic and nonlytic
mechanisms (6, 7). However, despite the strong antiviral
effects of CTLs, most infected individuals control viremia
poorly in the absence of antiviral treatment. Several cellular
and viral factors likely contribute to the failure of the immune
system to control HIV-1 infection (7). Moreover, there is
no clear association between viral loads and the breadth or
magnitude of CTL responses in humans (8–10), suggesting
either a lack of correlation between those two parameters,
or technical limitations in the assays used to measure specific
cellular immunity.
Thus, it is of interest to precisely document the repertoire
of viral epitopes recognized by HIV-1–specific CTLs.
Responses against all HIV-1 proteins have been reported,
with the strongest ones clustering in the more conserved
regions of Gag, Pol, and Nef. The viral proteins Vpu, Tat,
Rev, Vif, Vpr, and Env seemed initially less frequently
targeted (8, 9, 11–15). Recent studies performed using
autologous virus rather than reference strains (8, 9, 14, 16)
demonstrated that responses against variable regions of
regulatory and accessory viral proteins are more common
than previously reported. Notably, most, if not all, of the
HIV-1 epitope studies have only assessed proteins encoded
by primary open reading frames (ORFs) of the viral genome.
Nontraditional epitopes, derived from alternative reading
frames (ARFs) have been reported for influenza virus (17,
18); melanoma, gut, and renal cancers (19–22); and an
autoimmune disease (23). This is also the case for murine
AIDS, which is caused by a mixture of retroviruses called
LP-BM5. CTLs directed against a peptide encoded by a
 
 
 
2 ORF of a LP-BM5 
 
gag
 
 gene are generated during the
course of natural infection (24). Various transcriptional and
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translational mechanisms may account for ARF expression
and nontraditional epitope generation. These include cryp-
tic promoter activation, reinitiation of translation at down-
stream start codons, and ribosomal frameshifting (25).
Based on these observations, we asked whether nontra-
ditional CTL epitopes may be generated during HIV-1 in-
fection. First, we identified ARFs within the HIV-1 ge-
nome that potentially encode small polypeptides (ARF
polypeptides [ARFPs]). Using an algorithm for predicting
HLA-B7–restricted epitopes, we selected candidate pep-
tides encoded by these ARFPs. Their immunogenicity
was evaluated using HLA-B7 transgenic, H-2K
 
b
 
D
 
b
 
 double
knockout mice (HLA-B7
 
m
 
 
 
3
 
 mice; reference 26). One
such ARFP-derived peptide (Q9VF), encoded by a region
overlapping the 
 
gag
 
 gene, was processed and presented by
HIV-infected cells in vitro. In addition, CTLs recognizing
this epitope were found in HIV
 
 
 
 patients. Five additional
ARFP-derived epitopes derived from 
 
pol
 
 and 
 
env
 
 ARFs
were also studied. Altogether, these results reveal the exist-
ence of nontraditional mechanisms for HIV-1 epitope gen-
eration. They indicate that the extent of the cellular im-
mune response directed against HIV-1 may be broader
than initially thought.
 
Materials and Methods
 
Study Population. 
 
PBMCs were obtained from eight HLA-
B7
 
 
 
, hepatitis C virus (HCV)
 
 
 
, CMV
 
 
 
, and HIV-infected indi-
viduals (patients nos. 1–8) from the Hôpital Européen Georges
Pompidou with informed consent. Patients were asymptomatic
and undergoing antiretroviral therapy (see Table I for patients’
characteristics). Seven HIV
 
 
 
 HLA-B7
 
 
 
 (nos. 9a–9g) and one
HIV-infected HLA-B7
 
 
 
 (no. 10) individuals were also included
in the study. HLA-B7 phenotyping was performed using anti–
HLA-B7 ME.1 antibody (27). This phenotyping was confirmed
by PCR amplification and sequencing of the genomic DNA, us-
ing a previously described method (28).
 
Cell Culture. 
 
Ficoll-purified human PBMCs were either im-
mediately used in antigen presentation assays or grown in 96 well-
plates in RPMI 1640, supplemented with 10% human serum (In-
stitut Jacques Boy) and human IL-2 at 20 IU/ml (Roche).
Mouse CTL lines were derived from splenocytes of immu-
nized HLA-B7
 
m
 
 
 
3
 
 transgenic mice (26). In brief, these mice ex-
press a chimeric HLA-B0702 heavy chain with a murine 
 
 
 
3 do-
main, and their H-2K
 
b
 
 and H-2D
 
b
 
 class I-a genes have been
inactivated. Cells were cultured in RPMI 1640 supplemented
with 10% FBS (Dutscher) and stimulated every 10 d with pep-
tide-pulsed syngenic LPS lymphoblasts.
T2 (29), RMA (26), and T1 (174xCEM, CCR5
 
 
 
 LTR-
GFP
 
 
 
) cells were stably transfected with the HLA-B7
 
m
 
 
 
3
 
 con-
struct, yielding respectively T2-B7, RMA-B7, and T1-B7 cells,
and were used as antigen-presenting cells.
 
Viruses and Infections. 
 
HIV
 
LAI/stop
 
 was generated by introduc-
ing in HIV
 
LAI
 
 provirus a stop codon at position 3 in the ARFP
amino acid sequence without affecting the primary Gag amino
acid sequence, using Quickchange XL Site-directed Mutagenesis
kit (Stratagene). HIV
 
LAI
 
 and HIV
 
LAI/stop
 
 were produced by trans-
fecting the corresponding proviruses into 293T cells (30). 5 
 
 
 
10
 
6
 
 Jurkat and T1-B7 cells were infected with 500 ng of p24 for
3 h in culture medium containing 20 mM Hepes, pH 7.4, and 20
 
 
 
g/ml DEAE-dextran. Culture supernatants were collected ev-
ery 2–3 d and p24 content was measured by ELISA. After 5 d, in-
fected T1-B7 cells were used as antigen-presenting cells in
ELISPOT assays. At this time, 50% of the cells were positive for
intracellular p24.
 
Mouse CTL Induction. 
 
Peptide affinity for HLA-B0702 and
immunogenicity assays were performed as described previously
(26). In brief, HLA-B0702 binding of each peptide was assessed
in a FACS
 
®
 
-based assay measuring the stabilization of empty
HLA-B0702 molecules at the surface of 10
 
5
 
 T2-B7 cells, and
compared with the reference R10TV binding (CMV pp65
 
265
 
RPHERNGFTV
 
274
 
; reference 31) as follows: the lower the
relative affinity, the stronger the binding. Groups of six mice
were immunized with single experimental peptides (50 
 
 
 
g/
mouse) plus the helper peptide T13L (HBV-derived mouse IA
 
b
 
MHC class II epitope), and spleen cells were restimulated in vitro
(5 
 
 
 
g/ml of peptide). 6 d later, cytolytic activity was tested in a
4-h 
 
51
 
Cr release assay using peptide-pulsed RMA-B7 target cells.
Specific lysis was calculated as follows: (experimental 
 
 
 
 sponta-
neous release) (total 
 
 
 
 spontaneous release) 
 
 
 
 100.
 
Mouse CTL Recognition of Infected T1 Cells. 
 
80–2,000 mouse
CTLs were stimulated by 100,000 infected T1-B7
 
 
 
 cells, and
IFN-
 
 
 
 release was detected by ELISPOT assays. Two mouse
CTL lines specific for the HLA-B0702–restricted, known
Nef-derived epitope F10LR (Nef
 
68
 
FPVTPQVPLR
 
77
 
; refer-
ence 32) or for the CMV-derived epitope R10TV were used as
controls.
 
Human CTL Activity Assays. 
 
Ex vivo peptide stimulation of
human PBMCs was performed using HCV-derived HLA-B7–
restricted epitope G9AT (GPRLGVRAT; reference 33) as negative
control, phytohemagglutinin (Sigma-Aldrich) and CMV-derived
epitope T10AM (pp65
 
417
 
TPRVTGGGAM
 
426
 
; reference 31) as pos-
itive controls, and known HIV-1–derived epitopes described in the
Los Alamos Database as follows (http://www.hiv.lanl.gov/content/
hiv-db/mainpage.html): S9WV, p24
 
16
 
SPRTLNAWV
 
24
 
; T9ML,
p24
 
48
 
TPQDLNTML
 
56
 
; Y10LF, p6
 
36
 
YPLASLRSLF
 
45
 
; R10SI,
gp160
 
298
 
RPNNNTRKSI
 
307
 
; I9GL, gp160
 
843
 
IPRRIRQGL
 
851
 
; F10LR,
T10PL, Nef
 
128
 
TPGPGVRYPL
 
137
 
; R9AL, Nef
 
77
 
RPMTYKAAL
 
85
 
;
and F9GL, Vpr
 
34
 
FPRIWLHGL
 
42
 
. For ELISPOT assay, 2 
 
 
 
 10
 
5
 
PBMCs were incubated for 16 h at 37
 
 
 
C with individual peptides
(5 
 
 
 
 10
 
 
 
6
 
 M), and IFN-
 
 
 
 release was measured as described pre-
viously (34). For cytofluorimetry analysis, PBMCs were plated
for 2 h in V-bottom 96-well plates (600,000 cells/well) in IL-2–
containing medium (5 IU/ml) and loaded with peptides at
5 
 
 
 
g/ml. 10 
 
 
 
g/ml of brefeldin A (Sigma-Aldrich) was added for
6 h, and intracellular IFN-
 
 
 
 production was measured as de-
scribed previously (35) using the following mAbs: CD3-biotin,
CD8-APC antibody, CD4-PerCP, streptavidin-PE, and anti–
IFN-
 
 
 
–FITC (BD Biosciences). Cells were analyzed with a FACS-
Calibur™ cytometer (BD Biosciences). Percentage of IFN-
 
 
 
–
producing cells was obtained by gating on CD3
 
 
 
 CD4
 
 
 
 and
CD3
 
 
 
 CD8
 
 
 
 cells. For 
 
51
 
Cr release assay, 10
 
6
 
 PBMCs were
loaded with the relevant peptides at 5 
 
 
 
g/ml and cultured in
48-well plates. On day 3, 25 ng/ml recombinant human IL-7
(Sanofi-Synthelabo) was added. CTL lines were restimulated
twice (at 10-d intervals) with peptide-pulsed 
 
 
 
-irradiated autolo-
gous PHA-blasts (50 Gy) in IL-2–containing medium. Cytolytic
assays were performed as aforementioned using T2-B7 cells as
targets. G9AT peptide was used as a negative control.
 
Statistical Analysis. 
 
The nonparametrical Mann-Whitney test
was performed using Abacus Concepts, Stat View statistic soft-
ware. Differences were considered statistically significant when
P 
 
 
 
 0.05. 
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Results
 
Identification of Q9VF, a Potential MHC-I–restricted Epitope
Derived from an HIV-1 ARF.
 
In addition to the ORFs en-
coding the 10 major structural and regulatory viral proteins,
the HIV-1 genome contains multiple ARFs that potentially
encode small polypeptides (36). We asked whether immu-
nogenic epitopes may be generated from these polypep-
tides. Polypeptides derived from ARFs that begin with an
ATG codon and that present Kozak motifs (37) were ana-
lyzed using the SYFPEITHI algorithm (38) to predict
which ones might be presented by HLA-B0702. We first
identified a 
 
 
 
2 ORF within the 
 
gag
 
 gene encoding a po-
tential 52–amino acid polypeptide, which we named “Gag-
ARFP” for Gag-ARF–encoded polypeptide (Fig. 1 A).
Peptide Q9VF (Fig. 1 A, QPRSDTHVF), derived from
Gag-ARFP, stably binds to the HLA-B0702 (HLA-B7)
molecule with a relative affinity equivalent to the strong
Figure 1. Identification of an antigenic
epitope (Q9VF) derived from a nontradi-
tional HIV-1 reading frame. (A) Nucleotide
and amino acid sequences of a potential
alternative  reading frame (ARF) protein
encoded within the gag gene. Start and stop
codons are in bold, and the Kozak sequence
is underlined. Nucleotide numbering is
according to HIVLAI sequence. The pre-
dicted amino acid sequence of the corre-
sponding polypeptide (Gag-ARFP) is shown,
and the HLA-B7 potential epitope Q9VF is
underlined (bold). (B) Cytotoxic activity of
splenocytes from six HLA-B7 humanized
mice immunized with Q9VF synthetic
peptide. Splenocytes were tested using
RMA-B7 target cells pulsed with the Q9VF
peptide or with a nonrelevant CMV peptide
(R10TV) as a control. Data are mean   SD
of six mice and are representative of three in-
dependent experiments. Cytolytic responses
were considered positive when specific lysis
was  10% at an effector/target (E/T) ratio
of 30:1.
Figure 2. The Q9VF epitope from Gag-ARFP
is presented by HIV-infected cells. (A) IFN- 
ELISPOT assay was performed using T1-B7 cells
infected with HIVLAI or HIVLAI/stop or incubated
with the indicated synthetic peptide as stimulators.
Effector CTLs were splenocytes from HLA-B7
mice immunized with synthetic peptides corre-
sponding to Gag-ARFP (Q9VF), HIV-1 Nef
(F10LR), and CMV (R10TV) epitopes. Data are
mean    SD of triplicates for IFN- –producing
cells per 1,000 effectors and are representative of
three independent experiments. (B) Gag-ARFP is
not required for HIV replication in T cell lines.
The replication kinetics of HIVLAI and HIVLAI/stop
were measured in two human cell lines (T1-B7
and Jurkat) by measuring p24 production in the su-
pernatants at the indicated days after infection.
HIVLAI/Stop was derived from HIVLAI by inserting a
stop codon three nucleotides after the start codon
of the sequence encoding for Gag-ARFP. T1-B7
cells were derived from T1 cells and express the
HLA-B7m 3 protein. NI, noninfected cells.HIV-1 CD8  Epitopes from Alternative Reading Frames 1056
binding of reference CMV peptide R10TV (not depicted).
We found that transgenic mice expressing a human HLA-
B7 protein, but deficient in mouse MHC class I molecules
(HLA-B7m 3 mice) (26), produced a strong CTL response
against peptide-pulsed targets after immunization with
Q9VF (Fig. 1 B). Thus, Q9VF is a CTL epitope presented
by HLA-B7.
Q9VF Epitope Is Generated during HIV-1 Infection. We asked
whether Q9VF is processed and presented during HIV-1
infection. To this end, we derived a human cell line that
Figure 3. CTL responses to
Q9VF in HIV-infected individ-
uals. (A) IFN-  ELISPOT assay
was performed with PBMCs
from eight HIV-infected HLA-
B7  patients (nos. 1–8). As con-
trols, PBMCs from seven HIV 
HLA-B7  individuals (nos. 9a–9g)
and one HIV  HLA-B7  (no. 10)
individual were similarly ana-
lyzed. Responses against subject
no. 9a are represented. The test
was performed with the indi-
cated concentrations of PBMCs
and incubated with either CMV
(T10AM), Gag-ARFP (Q9VF),
Gag (Y10LF), or HCV (G9AT)
peptides (at 5  g/ml). Data are
means of duplicates. Responses
were considered positive when
IFN-  production was  50 spots/
106 PBMCs and exceeded at
least twofold background levels
(measured with the HCV pep-
tide). Similar results were ob-
tained with Q9VF for individ-
ual nos. 9a–9g (not depicted).
(B) IFN-  intracellular labeling
of PBMCs from HIV  HLA-
B7  patients (nos. 1 and 2) and
from an HIV  HLA-B7  indi-
vidual (no. 9a). Cells were incu-
bated with the indicated peptides,
stained for CD3, CD4, CD8,
and intracellular IFN-  expres-
sion and analyzed by flow cy-
tometry. The indicated percent
corresponds to the proportion of
IFN-   cells within CD3 CD8 
or CD3 CD4  populations.
Data are representative of three
independent experiments. (C) Cy-
totoxic activity of PBMCs from
two HIV-infected HLA-B7 
patients (nos. 1 and 2) and one
HIV  HLA-B7  individual (no.
9a).  51Cr release assay was per-
formed after two rounds of stim-
ulation of PBMCs with the indi-
cated peptides. Specific lysis was
measured by using as targets T2-
B7 cells pulsed with the corre-
sponding peptides (closed circles)
or with HCV G9AT peptide
(open circles) as a control. Data
are mean of duplicates at the
indicated  effector/target (E/T)
ratio, and are representative of
two independent experiments.
Cytolytic responses were consid-
ered positive when specific lysis
was  10% at an effector/target
ratio of 30:1.Cardinaud et al. 1057
stably expresses the HLA-B7m 3 protein (T1-B7). These
cells were infected with HIVLAI and used 5 d later as tar-
gets in an IFN-  ELISPOT assay. At this time,  50% of
the cells were productively infected, as assessed by intra-
cellular Gag p24 measurement (unpublished data). Effec-
tors were murine CTL lines obtained by immunization
of HLA-B7m 3 mice with either R10TV (a CMV pep-
tide), F10LR (a classical HLA-B7–restricted HIV-1 Nef
peptide), or Q9VF. CTLs recognizing HIV-1 Nef or
Gag-ARFP–derived peptides were activated after cocul-
ture with infected targets (Fig. 2 A). As expected, the
CMV peptide was not presented by HIV-infected T1-B7
cells.
To document the role of Gag-ARFP in viral replication
and Q9VF antigen presentation, we derived a mutant virus
(HIV-1LAI/stop) in which the expression of Gag-ARF was
abrogated by introducing a stop codon three nucleotides
after the start codon without affecting the gag reading
frame. Similar viral production and infectivity were ob-
served with HIV-1LAI and HIV-1LAI/stop in T1-B7 and in
Jurkat cells (Fig. 2 B) or in PBMCs infected with a lower
viral inoculum (unpublished data). Altogether, this indi-
cates that Gag-ARFP is not required for viral replication in
these cells. Importantly, no significant IFN-  production
was observed in an ELISPOT assay using Q9VF-restricted
mouse CTLs as effectors and HIV-1LAI/stop–infected cells as
targets (Fig. 2 A). In contrast, F10LR Nef-restricted CTLs
efficiently recognized both HIV-1LAI and HIV-1LAI/stop–
infected cells (Fig. 2 A). Parental T1 cells lacking HLA-B7m 3
and infected with HIVLAI were recognized by neither Gag-
ARFP nor Nef CTLs, indicating that antigen presentation
is appropriately MHC-I–restricted (unpublished data). Al-
together, these experiments indicate that, whereas Gag-
ARFP is not required for viral replication in T cell lines,
the Q9VF epitope is generated in HIV-1–infected cells and
is presented by MHC-I molecules, thus allowing activation
of specific CTLs.
HIV-1–infected Patients Develop a Q9VF-specific CTL Re-
sponse. It was important to determine whether a Q9VF
CTL response is generated during HIV infection in hu-
mans. We performed a cross-sectional study on patients
who had been infected for up to 16 yr. Virological and
clinical characteristics of eight HIV-infected HLA-B7  pa-
tients are presented in Table I (individuals nos. 1–8).
PBMCs were first analyzed in an IFN-  ELISPOT assay.
Incubation with peptides corresponding to well-character-
ized immunodominant HLA-B7–restricted HIV-1 Gag
(Y10LF) and CMV (T10AM) epitopes induced significant
IFN-  release in seven individuals (Fig. 3 A). Interestingly,
five out of the eight individuals (nos. 1–4 and no. 6)
showed significant activation with Q9VF. As controls,
PBMCs from seven HIV  HLA-B7  (nos. 9a–9g) individ-
uals and one HIV  HLA-B7  (no. 10) individual were an-
alyzed. None of them responded to Q9VF nor to the clas-
sical Gag Y10LF epitope (Fig. 3 A, individuals nos. 9a and
10). Differences between HIV  and HIV  HLA-B7  indi-
viduals were statistically significant (P   0.05).
We documented the Q9VF response further in HLA-
B7  persons by intracellular IFN-  labeling and flow cy-
tometry analysis (Fig. 3 B). IFN-  production was detected
in CD8  cells, and not in CD4  cells, from HIV-infected
individuals, but not from an HIV  control, indicating that
Table I. Patients’ Characteristics
HLA-B7 status
Patient Gender Age FACS® Sequence
Time since
HIV detection CD4 counta Viral loadb
Duration
of ART Treatmentc
yr cells/ml yr
1M 4 2    4 491  50 4 d4T-ddI-NEV
2M 3 3    9 642 1,776 5 3TC-d4T-NEV
3M 5 4    2.5 446  50 2.5 AZT/3TC
4M 4 1    10 463 53,362 9 AZT/3TC-RIT-SAQ
5M 4 9    16 616 18,815 15 d4T-ddI-NEV
6F 4 7   ND 14 603 20,427 11 d4T-3TC
7M 5 8    2.5 866 11,482 0 none
8M 4 7   ND 10 289 22,383 6 3TC-d4T-IND
10 M 33 – – 11 901 173 7 d4T-3TC
aPeripheral CD4  T lymphocyte count at the time of study.
bCopies of HIV-1 RNA per milliliter of plasma at the time of study.
cTreatment at the time of the study.
d4T, stavudine; ddI, didanosine; NEV, nevirapine; 3TC, lamivudine; AZT, zidovudine; RIT, ritonavir; SAQ, saquinavir; IND, indinavir; ART,
antiretroviral therapy.HIV-1 CD8  Epitopes from Alternative Reading Frames 1058
Q9VF is presented by MHC-I (Fig. 3 B). We also per-
formed a 51Cr release assay after two stimulations of
PBMCs with either the Q9VF, T10AM, or G9AT pep-
tides (Fig. 3 C). HIV-infected patients 1 and 2 displayed a
strong lytic activity against T2-B7 target cells loaded with
either Q9VF or the CMV-derived peptide, but did not re-
spond to the HCV peptide. The HIV  control donor only
responded to the CMV peptide. Therefore, the Q9VF
epitope derived from Gag-ARFP is generated during the
natural course of HIV-1 infection, and approximately half
of HIV-infected HLA-B7  persons tested displayed a CTL
response against it.
Identification of Additional ARFP-derived Epitopes. To ex-
tend these observations to other ARFPs, we selected
two overlapping epitopes from Pol-ARFP, a polypeptide
potentially encoded by a pol ORF  1 sequence (A9RL-
AAISPVLRL and S10PV-SPVLRLRPPV-), and three
epitopes from Env-ARFP, a polypeptide potentially en-
coded by env ORF  1 sequence (Fig. 4 A, Q10QM-QP-
PLYFVHQM-, G10QT-GPHMPVYPQT-, and M9PT-
MPVYPQTPT-). As for Q9VF, we tested these candidate
peptides for HLA-B7 affinity and for immunogenicity.
The five peptides generated CTL responses in immunized
HLA-B7m 3 mice, with efficiencies ranging from 1/6 to
6/6 responding mice (Fig. 4 B). We also asked whether
these peptides were generated in HIV-infected individu-
als. As a positive control, a panel of peptides correspond-
ing to known HIV epitopes, derived from Gag, Env, Nef,
and Vpr, was similarly tested. The ELISPOT profile of
IFN-  responses varied between the eight HLA-B7 
HIV-infected patients; however, a response for at least
one of the ARFP or traditional peptides was detected
in each individual (Fig. 5 A). For each ARFP-derived
epitope, a significant IFN-  response was detected in PBMCs
from at least five out of eight HIV-infected patients.
PBMCs from control individuals (seven HLA-B7  HIV 
and one HLA-B7  HIV ) did not produce significant
IFN-  levels upon exposure to these peptides (Fig. 5 A).
Comparing HIV  and HIV  HLA-B7  individuals indi-
cated that responses against each known or ARFP-derived
epitope were statistically significant (P   0.05). We fur-
ther characterized the CTL responses from individuals 1
and 2. Cultured PBLs were stimulated twice with peptide
and assayed for 51Cr release. We observed a strong lytic
Figure 4. Identification of five potential
epitopes derived from Pol  and Env 
ARFPs. (A) Nucleotide and amino acid
sequences of ARFPs encoded within the pol
and env genes. Start and stop codons are in
bold, and the Kozak sequence is underlined.
Nucleotide numbering is according to HIVLAI
sequence. The predicted amino acid se-
quences of the corresponding polypeptides
(Pol-ARFP and Env-ARFP) are shown,
and HLA-B7 potential epitopes (A9RL,
S10PV, Q10QM, G10QT, and M9PT) are
underlined. (B) Peptide relative affinity for
HLA-B7 and immunogenicity in HLA-B7
mice. Peptide relative affinity was calculated
as described in Materials and Methods. A
low relative affinity ( 5) denotes a strong
binding. To measure immunogenicity, six
HLA-B7 mice were immunized with each
peptide. Splenocytes were tested in a 51Cr
release cytotoxic assay using autologous
target cells pulsed with the corresponding
peptide or with a nonrelevant CMV peptide
as a control. The number of responding
mice is indicated. Data are mean   SD of
responder mice and are representative of
two independent experiments. Cytolytic
responses were considered positive when
specific lysis was  10% at an effector/target
(E/T) ratio of 30:1.Cardinaud et al. 1059
activity against target cells loaded with the different pep-
tides (Fig. 5 B). Altogether, these results demonstrate the
presence of an immune response against epitopes derived
from Env-ARFP, Pol-ARFP, and Gag-ARFP in HIV-1–
infected individuals.
Frequency of ARFP-derived Peptides in Naturally Occurring
HIV Isolates. Next, we examined whether sequences cor-
responding to the six ARFP-derived peptides were conserved
among the HIV-1 strains included in the Los Alamos database
(Fig. 6 A). Because the peptides studied here were derived
from the clade B HIVLAI strain, this analysis was first per-
formed on clade B strains and then on all clade (A–C) isolates
(Fig. 6 A). Except for Gag-ARFP, for which a stop codon
within the ARF was frequently observed (22 and 46% for
clade B and all clades, respectively), the reading frames en-
coding Pol-ARFP and Env-ARFP were generally open (96–
99% in all clades). Thus, the majority of circulating HIV-1
strains could express at least one of these ARFPs. Moreover,
the peptides that we selected in Pol- and Env-ARFP were
relatively well conserved among viral isolates, especially in
clade B (24–80%, depending on peptide; Fig. 6 A).
Notably, the Q9VF epitope (QPRSDTHVF) from HIVLAI
Gag-ARFP is not well conserved among other viral isolates
because the Q9VF/5N (QPRSNTHVF) encoding sequence
is present in 68% of clade B strains (Fig. 6 A). Therefore, we
asked whether Q9VF and Q9VF/5N-specific CTLs would
cross-react with the alternate peptide. To this end, we de-
rived mouse CTL lines against each peptide. The two pep-
tides showed affinity for HLA-B0702 and were comparably
immunogenic (unpublished data). In 51Cr release assays,
CTL lines specific for Q9VF and Q9VF/5N showed signifi-
cant cross-reactivity with the alternate peptide, but not with
a control CMV peptide (Fig. 6 B). Similar results were ob-
tained by ELISPOT analysis (unpublished data).
Figure 5. CTL responses to the six
ARFP-derived epitopes in HIV-infected
individuals. (A) IFN-  ELISPOT assay was
performed with the indicated peptides.
PBMCs from eight HIV-infected HLA-
B7  patients (nos. 1–8) and, as controls,
from seven HIV  HLA-B7  (nos. 9a–9g)
and one HIV  HLA-B7  (no. 10) individu-
als were analyzed. For controls, responses
against subjects 9d and 10 are shown (similar
results were obtained for individuals 9a–9g
for all HIV peptides tested; not depicted).
Results are presented as IFN-   cells/106
PBMCs. Responses were considered posi-
tive when IFN-  production was  50
spots/106 PBMCs and exceeded at least
twofold background levels (measured with
the HCV peptide). (white bars) Negative
responses (below background thresholds,
which are represented by the black line).
(gray bars) Weak responses (twofold back-
ground levels). (black bars) Strong responses
(at least threefold background levels). ( )
Responses  1,500 IFN-   cells. ND, not
determined. (B) Cytotoxic activity of
PBMCs from two HIV-infected HLA-B7 
patients (nos. 1 and 2). 51Cr release assay
was performed after two rounds of stimula-
tion of PBMCs with the indicated peptides.
Specific lysis was measured by using T2-B7
cells pulsed with the corresponding peptides
(closed circles) or with a HCV peptide
(open circles, G9AT) as a control. Data are
means of duplicates at the indicated effector/
target (E/T) ratio, and are representative of
two independent experiments. Cytolytic
responses were considered positive when
specific lysis was  10% at an effector/target
(E/T) ratio of 30:1.HIV-1 CD8  Epitopes from Alternative Reading Frames 1060
Discussion
We report that various nontraditional viral epitopes are
presented by MHC-I molecules in HIV-1–infected cells.
We first identified in the HIV-1 genome 3 ARFs poten-
tially encoding polypeptides from 34 to 52 amino acids in
length (which we named Gag-ARFP, Pol-ARFP, and
Env-ARFP). Various transcriptional and translational mech-
anisms, such as ribosomal frameshifting or internal AUG
translation initiation, may account for the biosynthesis of
these nontraditional polypeptides (for review see reference
25). For example, Gag-ARFP could be produced through
a ribosomal frameshifting from the gag sequence. Although
this remains to be formally proven, we noticed the pres-
ence of a conserved slippery site (UUUAAAU) upstream
of the Gag-ARFP start codon that may promote the frame-
shifting (39). Of note, we were unable to detect the pres-
ence of Gag-ARFP in HIV-infected cells (unpublished
data). This could be due to the poor sensitivity of the anti–
Gag-ARFP polyclonal antibodies that we have generated
(unpublished data). It is also conceivable that Gag-ARFP,
as well as other ARFPs, are short-lived and/or expressed at
low levels. These polypeptides could be related to defective
ribosomal products that are prematurely terminated or mis-
folded polypeptides rapidly degraded by the proteasome
(40, 41). Abrogating Gag-ARFP expression by inserting a
premature stop codon within the ARF did not affect viral
growth, indicating that this small protein is not essential for
the viral life cycle. Determining how Gag-ARFP, Pol-
ARFP, or Env-ARFP are produced and understanding
their biological function will require further investigations.
Using an algorithm, we defined six ARFP-derived epi-
topes putatively presented by the HLA-B7 molecule.
Several lines of evidence indicate that these unconventional
epitopes are of immunologic relevance. First, the six pep-
tides that we selected are immunogenic in HLA-B7 mice.
The repertoires of epitopes recognized by HLA-B7m 3
mouse and by human T cells are comparable in their
breadth (26); thus, this murine model offers a rapid and
convenient system to assess immunogenicity of various an-
tigens, including peptides. Second and most importantly,
the six epitopes are generated and recognized in HIV-1–
infected patients. This was demonstrated by ex vivo IFN- 
ELISPOT and intracellular labeling of patient PBMCs, as
well as by a 51Cr release test performed after a short period
of PBMC stimulation, which confirmed the killing activity
of peptide-stimulated cells. With each of the six ARFP-
derived peptides, a significant response was observed in
 50% of the HLA-B7  HIV-infected patients analyzed.
The breadth of the response varied between each individ-
ual, ranging from 1/6 to 6/6 peptides recognized. Third,
we show that the Gag-ARFP–derived epitope Q9VF is
generated in vitro in HIV-infected cells because infected
cells were recognized by Q9VF-specific CTLs. Moreover,
the Gag-ARFP negative mutant HIV strain carrying a pre-
mature stop codon was no longer able to activate these
Figure 6. Conservation of ARFP-derived
epitope sequences among circulating HIV-1
strains. (A) For each ARFP-derived peptide,
the percentage of HIV isolates carrying the
corresponding sequence is shown. Analysis
was performed among clade B and all clade
HIV-1 strains present in the Los Alamos
database. Strains without ARF translation
potential (absence of AUG start codon or
presence of stop codons within the ARFP)
are also indicated. The Gag-ARFP Q9VF
(QPRSDTHVF) has a major variant,
Q9VF/5N (QPRSNTHVF). WT, wild
type, corresponding to the HIVLAI sequence.
(B) Cross-reactivity between Q9VF and
Q9VF/5N peptides. Six HLA-B7 mice
were immunized with Q9VF or Q9VF/
5N. Splenocytes were tested using autologous
target cells pulsed with either Q9VF or
Q9VF/5N peptide or with a nonrelevant
CMV peptide as a control (R10TV). Data
are mean of six mice and are representative
of three independent experiments. Cytolytic
responses were considered positive when
specific lysis was  10% at an effector/target
(E/T) ratio of 20:1.Cardinaud et al. 1061
CTLs, indicating that Q9VF is generated from the ex-
pected ARF. It will be worth determining whether the
other ARFP-derived epitopes are similarly presented by
HIV-infected cells in culture. Altogether, these results indi-
cate that various nontraditional epitopes are presented by
MHC-I molecules in HIV-1–infected cells, leading to the
activation of specific CTLs.
A comprehensive analysis of naturally occurring viral se-
quences in the Los Alamos database revealed various pat-
terns of intraclade and interclade conservation of the six
selected peptides. Some peptides are highly conserved (64
and 80% intraclade B conservation for Env-ARFP–
derived M9PT and G10QT epitopes, respectively). Others
are less frequently encountered, such as Pol-ARFP–
derived A9RL and S10PV epitopes (24 and 29% intraclade
B conservation, respectively). The Gag-ARFP–derived
Q9VF peptide is infrequent among viral isolates, but its
cross-reactive variant Q9VF/5N is found in up to 68% of
clade B viruses. We have also performed a preliminary
analysis of the provirus sequences encountered in three of
the HLA-B7  patients studied here. In agreement with
the analysis of the Los Alamos database, we observed in
these patients a high variability of Gag-ARFP sequences,
which encoded mostly Q9VF/5N, and more rarely Q9VF
or other variant epitopes (unpublished data). Altogether,
these results indicate that ARFPs may generate either con-
served or variable epitopes, similar to primary ORF-
encoded epitopes. It is important to note that the observed
conservation of a given ARF sequence will depend not
only on immunological and virological selection pressures
exerted on its ARFP, but also on the protein encoded by
the corresponding primary ORF.
We have limited our analysis to epitopes presented by
HLA-B7 haplotypes and encoded by sequences beginning
with AUG and preceded by a consensus Kozak sequence.
One can expect that other nontraditional epitopes may be
presented by various HLA molecules. Different cryptic
translation mechanisms, such as non-AUG translation ini-
tiation (42), have been reported in other systems and
may be operative in HIV-1–infected cells as well (for re-
view see reference 43). Therefore, the repertoire of viral
epitopes is certainly much broader than previously thought
(44). Although these nontypical epitopes may be infre-
quent, we provide evidence here that they are generated
during natural HIV-1 infection. This underappreciated
source of epitopes should be studied more extensively
(e.g., by longitudinally monitoring CTL responses during
the course of HIV infection. Nontypical epitopes should
be taken into account when designing candidate vaccine
formulations.
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